The “Single-Use Bioreactors Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The global single-use bioreactors market reached a value of US$ 2.54 billion in 2021. Looking forward, the market is projected to reach a value of US$ 6.23 billion by 2027, exhibiting a CAGR of 15.50% from 2022-to 2027.
- ABEC Inc.
- Celltainer Biotech B.V.
- CESCO Bioengineering Co. Ltd.
- Distek Inc.
- Eppendorf SE
- General Electric Company
- Getinge AB
- Merck KGaA
- Pall Corporation (Danaher Corporation)
- PBS Biotech Inc.
- Sartorius AG
- Thermo Fisher Scientific Inc
Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different End-use sectors. These insights are included in the report as a major market contributor.
A single-use bioreactor (SUB), also known as a disposable bioreactor, relies on a disposable bag instead of a culture vessel made using stainless steel or glass. It is flexible and easy to use and install and requires fewer utility requirements, including steam and water. Besides this, it reduces labor costs, minimizes the risk of cross-contamination, and eliminates the cleaning process and validation issue. As a result, it finds extensive applications in contract research organizations (CROs) and contracts manufacturing organizations (CMOs) worldwide.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
SUBs are employed in the pharmaceutical industry for media and buffer preparation, cell harvesting, filtration, purification, and virus inactivation. They are also used in academic and commercial-scale laboratories for drug discovery, biofuel manufacturing, and the development of vaccines and antibodies. This, in confluence with the burgeoning biopharmaceutical industry, represents one of the key factors impelling the growth of the market. Moreover, autoclaving a conventional bioreactor can become a lengthy, costly, and inconsistent pharmaceutical manufacturing process.
However, SUBs utilize pre sterilized bioprocess bags and consequently reduce the additional costs and time of sterilization. Besides this, as they have fewer moving parts than conventional bioreactors, SUBs are less expensive to maintain. Apart from this, SUBs have a lower overall impact on the environment compared to stainless steel equipment. This, coupled with the growing number of clinical trials around the world, is catalyzing their demand across the globe.
Furthermore, leading players are increasingly focusing on product innovations and mergers and acquisitions (M&A) to expand their customer base and increase their geographical presence. This, along with the rising adoption of single-use technology (SUT), is augmenting the overall sales and profitability.